126 related articles for article (PubMed ID: 9038376)
1. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation.
Burke CL; Lemmon MA; Coren BA; Engelman DM; Stern DF
Oncogene; 1997 Feb; 14(6):687-96. PubMed ID: 9038376
[TBL] [Abstract][Full Text] [Related]
2. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo.
Lofts FJ; Hurst HC; Sternberg MJ; Gullick WJ
Oncogene; 1993 Oct; 8(10):2813-20. PubMed ID: 8104327
[TBL] [Abstract][Full Text] [Related]
3. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
Zhang HT; O'Rourke DM; Zhao H; Murali R; Mikami Y; Davis JG; Greene MI; Qian X
Oncogene; 1998 Jun; 16(22):2835-42. PubMed ID: 9671404
[TBL] [Abstract][Full Text] [Related]
4. Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation.
Qian X; Dougall WC; Fei Z; Greene MI
Oncogene; 1995 Jan; 10(1):211-9. PubMed ID: 7824275
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic activation of the PDGF beta receptor by the transmembrane domain of p185neu*.
Petti LM; Irusta PM; DiMaio D
Oncogene; 1998 Feb; 16(7):843-51. PubMed ID: 9484775
[TBL] [Abstract][Full Text] [Related]
6. Dimer interface of transmembrane domains for neu/erbB-2 receptor dimerization and transforming activation: a model revealed by molecular dynamics simulations.
Sajot N; Genest M
J Biomol Struct Dyn; 2001 Aug; 19(1):15-31. PubMed ID: 11565846
[TBL] [Abstract][Full Text] [Related]
7. The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling.
Kumagai T; Davis JG; Horie T; O'Rourke DM; Greene MI
Proc Natl Acad Sci U S A; 2001 May; 98(10):5526-31. PubMed ID: 11320205
[TBL] [Abstract][Full Text] [Related]
8. Specific locations of hydrophilic amino acids in constructed transmembrane ligands of the platelet-derived growth factor beta receptor.
Freeman-Cook LL; Edwards AP; Dixon AM; Yates KE; Ely L; Engelman DM; Dimaio D
J Mol Biol; 2005 Jan; 345(4):907-21. PubMed ID: 15588835
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein.
Qian X; O'Rourke DM; Zhao H; Greene MI
Oncogene; 1996 Nov; 13(10):2149-57. PubMed ID: 8950982
[TBL] [Abstract][Full Text] [Related]
10. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
Weiner DB; Kokai Y; Wada T; Cohen JA; Williams WV; Greene MI
Oncogene; 1989 Oct; 4(10):1175-83. PubMed ID: 2571965
[TBL] [Abstract][Full Text] [Related]
11. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation.
Groysman M; Nagano M; Shaanan B; Katzav S
Oncogene; 1998 Sep; 17(12):1597-606. PubMed ID: 9794237
[TBL] [Abstract][Full Text] [Related]
12. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.
Wai DH; Knezevich SR; Lucas T; Jansen B; Kay RJ; Sorensen PH
Oncogene; 2000 Feb; 19(7):906-15. PubMed ID: 10702799
[TBL] [Abstract][Full Text] [Related]
13. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
[TBL] [Abstract][Full Text] [Related]
14. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies.
Dougall WC; Qian X; Peterson NC; Miller MJ; Samanta A; Greene MI
Oncogene; 1994 Aug; 9(8):2109-23. PubMed ID: 7913542
[TBL] [Abstract][Full Text] [Related]
15. A basic peptide within the juxtamembrane region is required for EGF receptor dimerization.
Aifa S; Aydin J; Nordvall G; Lundström I; Svensson SP; Hermanson O
Exp Cell Res; 2005 Jan; 302(1):108-14. PubMed ID: 15541730
[TBL] [Abstract][Full Text] [Related]
16. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
Weiner DB; Liu J; Cohen JA; Williams WV; Greene MI
Nature; 1989 May; 339(6221):230-1. PubMed ID: 2654648
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity.
Tognon CE; Mackereth CD; Somasiri AM; McIntosh LP; Sorensen PH
Mol Cell Biol; 2004 Jun; 24(11):4636-50. PubMed ID: 15143160
[TBL] [Abstract][Full Text] [Related]
18. Activation of phosphatidylinositol 3-kinase is necessary for differentiation of FDC-P1 cells following stimulation of type III receptor tyrosine kinases.
Kubota Y; Angelotti T; Niederfellner G; Herbst R; Ullrich A
Cell Growth Differ; 1998 Mar; 9(3):247-56. PubMed ID: 9543391
[TBL] [Abstract][Full Text] [Related]
19. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
Michieli P; Basilico C; Pennacchietti S; Maffè A; Tamagnone L; Giordano S; Bardelli A; Comoglio PM
Oncogene; 1999 Sep; 18(37):5221-31. PubMed ID: 10498872
[TBL] [Abstract][Full Text] [Related]
20. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
Vempati S; Reindl C; Wolf U; Kern R; Petropoulos K; Naidu VM; Buske C; Hiddemann W; Kohl TM; Spiekermann K
Clin Cancer Res; 2008 Jul; 14(14):4437-45. PubMed ID: 18628457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
